- Global Pharma News & Resources

Personalis, Inc. to Present at the 3rd Annual NeoAG Summit Boston

Personalis, Inc., a leader in advanced genomics for precision oncology, today announced that they are scheduled to present at the upcoming NeoAG Summit in Boston, MA on Thursday, November 15, 2018 at 4 PM ET.

The presentation, entitled “ImmunoID NeXT Platform: Improving Neoantigen Prediction, TME Assessment, and ctDNA Detection for Vaccine Development,” will introduce Personalis’ new ImmunoID NeXT Platform and discuss how it facilitates highly accurate neoantigen identification, optimal MHC-binding prediction and ranking, and the assessment of the tumor microenvironment and tumor escape mechanisms that may impact response to personalized therapeutics.

ImmunoID NeXT is the first and only platform to provide comprehensive analysis of both a tumor and its microenvironment from a single sample. The platform can be used to investigate the key tumor- and immune-related areas of cancer biology; consolidating multiple oncology biomarker assays into one. This maximizes the biological information that can be generated from a precious tumor specimen.

The presentation will be delivered by Sean Boyle, PhD; Director, Bioinformatics Applications.

About Personalis, Inc.

Personalis, Inc. is a leader in advanced genomics for precision oncology translational research and clinical trials, dedicated to enabling the development of the next generation of oncology therapeutics. The company’s ImmunoID NeXT Platform comprehensively characterizes the tumor and the tumor microenvironment, facilitating the analysis of key predictive and investigational oncology biomarkers from a single sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit and follow Personalis on Twitter (@PersonalisInc).

View source version on

Editor Details

Last Updated: 14-Nov-2018